Andrew Moreno

DocwireNews

A new retrospective analysis of real-world patients with lower-risk myelodysplastic syndromes (MDS) has assessed the role of clonal dynamics in this disease. It examined the clinical impact from genetic lesion events, namely clonal evolution and expansion of existing clones. The findings were published in HemaSphere.The authors wrote that they sought to fill a current knowledge gap about lower-risk disease, &ldquo;since published data on clonal dynamics in MDS is mainly based on high&#8208;risk MDS with leukemic transformation thus not covering the important early phases of MDS.&rdquo;The cohort for the analysis included 68 patients with lower-risk MDS and had a median follow-up of 40.5 months. Among them, the median number of timepoints where the patients were evaluated for clonal evolution and expansion of existing clones was 7.5. These genetic events were detected using chromosomal banding analysis, fluorescence in situ hybridization, molecular karyotyping, and sequencing.During the study, 47 clonal evolution events occurred across 30 patients of the cohort. The authors calculated that these patients had a clonal dynamics rate of one event per four years.The authors found that patients who had at least one clonal evolution event were more likely to undergo subsequent treatment. They remarked as noteworthy that in the cohort, &ldquo;clonal evolution did not correlate with inferior outcomes, which could be reasonably explained by clonal dynamics detection triggering the subsequent start of a disease&#8208;modifying therapy.&rdquo;ReferenceMazzeo P, Ganster C, Wiedenh&ouml;ft J, et al. Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDS. Hemasphere. 2024;8(9):e70014. Published 2024 Sep 23. doi:10.1002/hem3.70014

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Apitegromab Improved Motor Function in Type 2/3 Spinal Muscular Atrophy

Latest News

Clonal Dynamics Event Detection May Spur Treatment in Lower-Risk MDS

Most of the research performed up to this point on the influence of clonal dynamics in MDS has focused on high-risk disease.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe